JP2021524744A5 - - Google Patents

Info

Publication number
JP2021524744A5
JP2021524744A5 JP2020564841A JP2020564841A JP2021524744A5 JP 2021524744 A5 JP2021524744 A5 JP 2021524744A5 JP 2020564841 A JP2020564841 A JP 2020564841A JP 2020564841 A JP2020564841 A JP 2020564841A JP 2021524744 A5 JP2021524744 A5 JP 2021524744A5
Authority
JP
Japan
Prior art keywords
cancer
gene
carcinoma
adenocarcinoma
gene signature
Prior art date
Application number
JP2020564841A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021524744A (ja
JPWO2019226514A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/033052 external-priority patent/WO2019226514A2/en
Publication of JP2021524744A publication Critical patent/JP2021524744A/ja
Publication of JP2021524744A5 publication Critical patent/JP2021524744A5/ja
Publication of JPWO2019226514A5 publication Critical patent/JPWO2019226514A5/ja
Priority to JP2024034926A priority Critical patent/JP2024053048A/ja
Pending legal-status Critical Current

Links

JP2020564841A 2018-05-21 2019-05-20 分子遺伝子シグネチャーとその使用方法 Pending JP2021524744A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024034926A JP2024053048A (ja) 2018-05-21 2024-03-07 分子遺伝子シグネチャーとその使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862674285P 2018-05-21 2018-05-21
US62/674,285 2018-05-21
US201862747853P 2018-10-19 2018-10-19
US62/747,853 2018-10-19
PCT/US2019/033052 WO2019226514A2 (en) 2018-05-21 2019-05-20 Molecular gene signatures and methods of using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024034926A Division JP2024053048A (ja) 2018-05-21 2024-03-07 分子遺伝子シグネチャーとその使用方法

Publications (3)

Publication Number Publication Date
JP2021524744A JP2021524744A (ja) 2021-09-16
JP2021524744A5 true JP2021524744A5 (https=) 2022-05-30
JPWO2019226514A5 JPWO2019226514A5 (https=) 2022-05-30

Family

ID=67002367

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020564841A Pending JP2021524744A (ja) 2018-05-21 2019-05-20 分子遺伝子シグネチャーとその使用方法
JP2024034926A Pending JP2024053048A (ja) 2018-05-21 2024-03-07 分子遺伝子シグネチャーとその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024034926A Pending JP2024053048A (ja) 2018-05-21 2024-03-07 分子遺伝子シグネチャーとその使用方法

Country Status (7)

Country Link
US (1) US20210363590A1 (https=)
EP (1) EP3797173A2 (https=)
JP (2) JP2021524744A (https=)
CN (1) CN112771177A (https=)
AU (1) AU2019275404A1 (https=)
CA (1) CA3100200A1 (https=)
WO (1) WO2019226514A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210121016A (ko) * 2018-12-21 2021-10-07 나노스트링 테크놀로지스, 인크. 병리학적 표본의 모바일 디지털 공간 프로파일링을 위한 방법, 장치, 시스템 및 디바이스
US20230062248A1 (en) * 2020-01-31 2023-03-02 Allarity Therapeutics Europe ApS Methods for predicting ixabepilone responsiveness in cancer patients
ES2849965B2 (es) * 2020-02-21 2023-11-17 Fundacion Para La Investig E Innovacion Biosanitaria De Asturias Finba Ispa Metodo para predecir o pronosticar la respuesta al tratamiento del cancer
WO2021228888A1 (en) * 2020-05-12 2021-11-18 Asylia Diagnostics Biomarkers for hyperprogressive disease and therapy response after immunotherapy
US20230250173A1 (en) * 2020-07-01 2023-08-10 Pfizer Inc. Biomarkers for pd-1 axis binding antagonist therapy
WO2022012420A1 (zh) * 2020-07-17 2022-01-20 信达生物制药(苏州)有限公司 一种核苷酸组合及其应用
US12263233B2 (en) * 2020-10-19 2025-04-01 Washington University Compositions and methods for modulating Myc target protein 1
TW202241469A (zh) * 2021-02-20 2022-11-01 美商凱特製藥公司 免疫療法
EP4302093A1 (en) * 2021-03-01 2024-01-10 Genentech, Inc. Diagnostic methods and methods of treatment of ovarian cancer
WO2022211620A1 (en) * 2021-04-01 2022-10-06 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Cd4/il-2 biomarker.
CN114231623B (zh) * 2021-10-14 2023-09-08 福建中医药大学 Palmdelphin在制备人结直肠癌检测及治疗产品中的应用
WO2023070121A1 (en) * 2021-10-22 2023-04-27 The Wistar Institute Of Anatomy And Biology Compositions and methods for treatment of mic60 depleted cancers and metastasis
CN113913507A (zh) * 2021-10-29 2022-01-11 温州医科大学附属第一医院 Ccl3蛋白作为评估非酒精性脂肪性肝病炎症水平及疾病进展的生物标志物的应用
WO2023092119A2 (en) * 2021-11-22 2023-05-25 Ludwig Institute For Cancer Research Ltd Methods for predicting responsiveness to a cancer therapy
US20230257825A1 (en) * 2022-02-04 2023-08-17 City Of Hope Breast cancer biomarkers and methods of use
US20260002216A1 (en) * 2022-02-18 2026-01-01 London Health Sciences Centre Research Inc. Immune Classification Tool for Determining Survival Outcomes in Cancer
CN115896290B (zh) * 2022-11-29 2023-11-24 中国人民解放军海军军医大学 Trim21基因检测在肿瘤诊断、治疗选择和预后评估中的应用
WO2024227553A1 (en) * 2023-05-01 2024-11-07 The Chancellor, Masters And Scholars Of The University Of Oxford Biomarkers for use in cancer treatment and predicting responsiveness to a cancer therapy
WO2024234348A1 (en) * 2023-05-17 2024-11-21 Yanjun Wang Biomarker for immune checkpoint blockade therapy in nsclc
CN119685476A (zh) * 2024-05-29 2025-03-25 深圳湾实验室 一种与癌症预后相关的基因标志物及其应用
CN120775978A (zh) * 2025-03-14 2025-10-14 浙江省肿瘤医院 乳头状甲状腺癌早期预测标志物的筛选方法及应用

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
EP0491007B1 (en) 1989-09-08 1996-03-13 The Johns Hopkins University Structural alterations of the egf receptor gene in human gliomas
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
EP0659439B1 (en) 1993-12-24 2001-10-24 MERCK PATENT GmbH Immunoconjugates
US5679683A (en) 1994-01-25 1997-10-21 Warner-Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5910486A (en) 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
MX9707453A (es) 1995-03-30 1997-12-31 Pfizer Derivados de quinazolina.
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508537D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
AU6267896A (en) 1995-06-07 1996-12-30 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth oftumors
MX9800215A (es) 1995-07-06 1998-03-31 Novartis Ag Pirrolopirimidas y procesos para su preparacion.
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
HU228446B1 (en) 1996-04-12 2013-03-28 Warner Lambert Co Kinazoline derivatives as irreversible inhibitors of protein-kinase, pharmaceutical compositions containing these compounds and use thereof
ID19609A (id) 1996-07-13 1998-07-23 Glaxo Group Ltd Senyawa-senyawa heterosiklik
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
ATE241986T1 (de) 1997-05-06 2003-06-15 Wyeth Corp Verwendung von chinazolin verbindungen zur behandlung von polyzystischer nierenkrankheit
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
CN1278176A (zh) 1997-11-06 2000-12-27 美国氰胺公司 喹唑啉衍生物作为用于治疗结肠息肉的酪氨酸激酶抑制剂的应用
WO2000031048A1 (en) 1998-11-19 2000-06-02 Warner-Lambert Company N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases
US7473767B2 (en) 2001-07-03 2009-01-06 The Institute For Systems Biology Methods for detection and quantification of analytes in complex mixtures
AU2003221684A1 (en) 2002-04-08 2003-10-27 Smithkline Beecham Corporation Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor
CN1852974A (zh) * 2003-06-09 2006-10-25 密歇根大学董事会 用于治疗和诊断癌症的组合物和方法
WO2005071419A2 (en) * 2004-01-16 2005-08-04 Ipsogen Protein expression profiling and breast cancer prognosis
EP1930414B1 (en) * 2005-09-08 2012-07-18 Medinet Co., Ltd. Method for activation treatment of antigen-presenting cell
US8986926B2 (en) 2005-12-23 2015-03-24 Nanostring Technologies, Inc. Compositions comprising oriented, immobilized macromolecules and methods for their preparation
EP1963531B1 (en) 2005-12-23 2011-09-21 Nanostring Technologies, Inc. Nanoreporters and methods of manufacturing and use thereof
JP5081232B2 (ja) 2006-05-22 2012-11-28 ナノストリング テクノロジーズ， インコーポレイテッド ナノレポーターを分析するためのシステムおよび方法
US20090076734A1 (en) * 2007-03-22 2009-03-19 Torres-Roca Javier F Gene Signature for the Prediction of Radiation Therapy Response
US8415102B2 (en) 2007-04-10 2013-04-09 Nanostring Technologies, Inc. Methods and computer systems for identifying target-specific sequences for use in nanoreporters
US8519115B2 (en) 2008-08-14 2013-08-27 Nanostring Technologies, Inc. Stable nanoreporters
WO2010076788A2 (en) * 2008-12-29 2010-07-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of predicting responsiveness to interferon treatment and treating hepatitis c infection
WO2011047087A2 (en) 2009-10-13 2011-04-21 Nanostring Technologies, Inc. Protein detection via nanoreporters
WO2012129488A2 (en) * 2011-03-23 2012-09-27 Virginia Commonwealth University Gene signatures associated with rejection or recurrence of cancer
GB201217892D0 (en) 2012-10-05 2012-11-21 Virttu Biolog Ltd Treatment of cancer
SG11201502778TA (en) * 2012-10-12 2015-05-28 Agency Science Tech & Res Method of prognosis and stratification of ovarian cancer
AU2014278152A1 (en) 2013-06-14 2015-12-24 Nanostring Technologies, Inc. Multiplexable tag-based reporter system
WO2016044189A1 (en) * 2014-09-15 2016-03-24 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonist and il-17 binding antagonists
WO2016049276A1 (en) * 2014-09-25 2016-03-31 Moffitt Genetics Corporation Prognostic tumor biomarkers
EP3230498B1 (en) * 2014-12-09 2023-01-18 Merck Sharp & Dohme LLC System and methods for deriving gene signature biomarkers of response to pd-1 antagonists
JP2018503373A (ja) * 2014-12-30 2018-02-08 ジェネンテック， インコーポレイテッド がんの予後診断及び治療のための方法及び組成物
RS61152B2 (sr) * 2015-05-12 2024-06-28 Hoffmann La Roche Terapeutski i dijagnostički postupci za lečenje raka
WO2017015099A1 (en) 2015-07-17 2017-01-26 Nanostring Technologies, Inc. Simultaneous quantification of gene expression in a user-defined region of a cross-sectioned tissue
WO2017096458A1 (en) * 2015-12-07 2017-06-15 Ontario Institute For Cancer Research (Oicr) Immune gene signature predictive of anthracycline benefit
WO2017216559A1 (en) * 2016-06-14 2017-12-21 Almac Diagnostics Limited Predicting responsiveness to therapy in prostate cancer
CA3040194A1 (en) * 2016-10-13 2018-04-19 Dana-Farber Cancer Institute, Inc. Compositions and methods for predicting response and resistance to ctla4 blockade in melanoma using a gene expression signature
EP3622092A4 (en) * 2017-05-11 2021-06-23 The Broad Institute, Inc. METHODS AND COMPOSITIONS OF USE OF CD8 + TUMOR-INFILTRATING LYMPHOCYTE SUBTYPES AND GENE SIGNATURES THEREOF
JP2021521439A (ja) * 2018-04-13 2021-08-26 エックス４ ファーマシューティカルズ， インコーポレイテッド がん血清バイオマーカーおよびその使用方法

Similar Documents

Publication Publication Date Title
JP2021524744A5 (https=)
Kato et al. Analysis of circulating tumor DNA and clinical correlates in patients with esophageal, gastroesophageal junction, and gastric adenocarcinoma
JPWO2019226514A5 (https=)
Tu et al. Assessment of the expression of the immune checkpoint molecules PD‐1, CTLA4, TIM‐3 and LAG‐3 across different cancers in relation to treatment response, tumor‐infiltrating immune cells and survival
Mak et al. A patient-derived, pan-cancer EMT signature identifies global molecular alterations and immune target enrichment following epithelial-to-mesenchymal transition
Guibert et al. Monitoring of KRAS-mutated ctDNA to discriminate pseudo-progression from true progression during anti-PD-1 treatment of lung adenocarcinoma
Gay et al. Giving AXL the axe: targeting AXL in human malignancy
Della Corte et al. Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures
Sideras et al. PD-L1, Galectin-9 and CD8+ tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma
Sato et al. DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells
Byers et al. An epithelial–mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance
Giovannetti et al. Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non–small cell lung cancer patients treated with gefitinib
Park et al. MicroRNA-9 suppresses cell migration and invasion through downregulation of TM4SF1 in colorectal cancer
Birnboim-Perach et al. Using Combination therapy to overcome diverse challenges of Immune Checkpoint Inhibitors treatment
Li et al. DCUN1D1 facilitates tumor metastasis by activating FAK signaling and up-regulates PD-L1 in non-small-cell lung cancer
La Salvia et al. HER2-targeted therapy: an emerging strategy in advanced colorectal cancer
JP2016534157A5 (https=)
Greil et al. Reactivation of dormant anti-tumor immunity–a clinical perspective of therapeutic immune checkpoint modulation
Lin et al. Advances in immuno-oncology biomarkers for gastroesophageal cancer: Programmed death ligand 1, microsatellite instability, and beyond
US20140155397A1 (en) Emt signatures and predictive markers and method of using the same
Kwon et al. Programmed death ligand-1 and MET co-expression is a poor prognostic factor in gastric cancers after resection
Hong et al. Angiogenesis-related microRNAs in colon cancer
Wu et al. TOPK promotes the growth of esophageal cancer in vitro and in vivo by enhancing YB1/eEF1A1 signal pathway
Yao et al. Pan-cancer biomarkers: changing the landscape of molecular testing
Necchi et al. Association of androgen receptor expression on tumor cells and PD-L1 expression in muscle-invasive and metastatic urothelial carcinoma: insights for clinical research